Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Articles|September 14, 2010
Use of ECT and Other Brain Stimulants in Bipolar Disorder
Advertisement
Video courtesy of
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
4
Sabirnetug Misses Primary Endpoint in Phase 2 Alzheimer Disease Trial
5